Astatine-211: production and availability (Q27015038)

Pruszynski M

series ordinal

2

1 reference

language of work or name

1 reference

July 2011

1 reference

Current radiopharmaceuticals

published in

1 reference

volume

4

1 reference

issue

3

1 reference

page(s)

177-85

1 reference

Astatine Radiopharmaceuticals: Prospects and Problems

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

28 September 2017

Polonium-210 as a poison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Preparation of a biologically stable and immunogenically competent astatinated protein

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Astatine Standard Redox Potentials and Speciation in Acidic Medium

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Optimisation study of alpha-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Incorporation of thiosemicarbazide in Amberlite IRC-50 for separation of astatine from alpha-irradiated bismuth oxide

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503149

Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination

28 November 2018

1 reference

12 December 2020

Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models

1 reference

12 December 2020

Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets

1 reference

12 December 2020

Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At

1 reference

12 December 2020

Which radionuclides will nuclear oncology need tomorrow?

1 reference

12 December 2020

A new internal target system for production of (211)At on the cyclotron U-120M

1 reference

12 December 2020

Experimental study of the cross-sections of alpha-particle induced reactions on 209Bi

1 reference

12 December 2020

Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields

1 reference

12 December 2020

Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction

1 reference

12 December 2020

Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At

1 reference

12 December 2020

10.2174/1874471011104030177

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

22201707

1 reference